Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform
Amount Raised
$50 Million
Round Type
Series B
San DiegoBiotechnologyTherapeuticsDescription
Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced that it has closed a $50 million Series B financing (assuming exercise of warrant). In addition to receiving funding from existing Cullgen investors, five new prominent international venture capital firms also participated in the financing, including the lead investor, 3E Bioventures Capital, as well as Heights Capital Management (an affiliate of Susquehanna International Group), Octagon Capital, MSA Capital and South China Venture Capital. The financing will support the development of Cullgen’s technology platform and internal pipeline of targeted protein degraders in oncology and other diseases. Cullgen is also pleased to announce that Frank Yan, from 3E Bioventures, will be joining Cullgen’s board of directors.
Quick answer
Cullgen raised $50 Million in a Series B round, dated February 25, 2021. Cullgen is based in San Diego, California, United States.
- How much did Cullgen raise?
- Cullgen raised $50 Million in a Series B round on February 25, 2021.
- What does Cullgen do?
- Cullgen Inc. is a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology.
- Where is Cullgen based and how big is it?
- Cullgen is based in San Diego, California, United States. Fundz records about 30 employees.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Cullgen that raised within 45 days of this round, from Fundz verified event records.
- Aura Biosciences, Inc. raised $80M on April 6, 2021.
- Artiva Biotherapeutics raised $120M on April 5, 2021.
- AbSci Corp raised $125M on March 30, 2021.
- Chemomab Therapeutics Ltd raised $45M on March 30, 2021.
- INBRAIN Neuroelectronics raised $17M (Series A) on March 30, 2021.
- Qihan Biotech raised $67M (Series A) on March 29, 2021.
Who to call at Cullgen, and when
A new round usually means Cullgen is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Cullgen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Cullgen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Cullgen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Cullgen raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansCullgen raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.